Abstract: The present invention relates to an immediate release tablet composition comprising axitinib form IV characterized by an XRPD pattern comprising the peaks at about 8.9, 12.0, 14.6, 15.2, 15.7, 17.8, 19.1, 20.6, 21.6, 23.2, 24.2, 24.9, 26.1 and 27.5±0.1 degrees 2?, when measured with Cu K?1 radiation and one or more pharmaceutically acceptable excipients, wherein the composition exhibits a dissolution rate between 40% and 70% in 30 minutes when tested in 900 ml 0.01 N hydrochloric acid pH 2.0 at 37° C., 75 rpm in a USP apparatus II.

Abstract: Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.

Abstract: Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution.

Abstract: This application provides, among other things, novel aqueous oral care compositions useful for combining and delivering poorly compatible ingredients, for example to deliver effective levels of cationic antibacterial agents in combination with anionic polymers that protect against erosion and staining, by addition of a stabilizing amount of a polyamine, e.g., lysine, and methods for making and using the same.

Abstract: The present invention relates to nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).

Abstract: The invention relates to a nanostructured active ingredient carrier system, in particular for reducing cytotoxic properties owing to the use of sheath polymer and the transport resulting therefrom, for interactions with cell membranes during the transport of hydrophilic constituents and, in connection therewith, the generation of an early endosomal release of the interaction complex from the carrier system. The problem addressed by the present invention is that of specifying a nanostructured active ingredient carrier system which avoids the disadvantages of the prior art and in particular permits a reduction in cytotoxic properties owing to the use of a sheath polymer and the transport resulting therefrom.

Abstract: Compositions, methods, and applications for single component systems for the formation of in situ hydrogels are described. The single component systems are effective for forming stable, single solutions containing precursors providing both electrophilic and nucleophilic groups that chemically crosslink on contact with physiological fluids associated with vital physiological tissue. The single component systems can be applied using various delivery vehicles, including injections, needle and needless catheters, and sprays. The single component systems can be useful for enabling multiple injections from a single syringe through a small gauge needle or other dispenser. Methods for transcervical installation of in situ formed hydrogels into one or more fallopian tubes are described.

Abstract: Systems and methods of using and imaging shear-thinning biomaterial compositions are provided. More particularly, systems and methods of providing reversible birth control and/or for delivering therapeutics to reproductive organs are provided. A method includes administering a biomaterial into fallopian tubes, uterus, or vas deferens of the subject, where the biomaterial is a shear-thinning nanocomposite.

Abstract: The present invention relates to polymersomes comprising a soluble encapsulated antigen, wherein said soluble encapsulated antigen is selected from the group consisting of: a polypeptide, a carbohydrate, a polynucleotide and combinations thereof. The present invention further relates to a method for production of encapsulated antigens in a polymersome as well as to polymersomes produced by said method. The present invention further relates to compositions comprising a polymersome of the present invention, isolated antigen presenting cells or hybridoma cells exposed to the polymersome or composition of the present invention. The present invention also relates to vaccines comprising polymersomes of the present invention, methods of eliciting an immune response or methods for treatment, amelioration, prophylaxis or diagnostics of a cancer, autoimmune or infectious disease, comprising providing polymersomes of the present invention.

Abstract: The present application discloses a liquid composition for cryopreservation of a biological material comprising a polar aprotic solvent, a monohydric or polyhydric alcohol, an unbranched polysaccharide, a branched polysaccharide; and polyvinyl alcohol. Further provided are uses of said liquid composition for cryopreservation of abiological material and methods for preserving a biological material using said liquid composition.

Abstract: Disclosed are: a method for suppressing adhesion of air harmful substances, including applying a metal oxide (A) having an average primary particle diameter dA of 800 nm or less to skin in an amount of 0.03 mg/cm2 or more to suppress adhesion of air pollutants to the skin, and a method for suppressing adhesion of air pollutants, including applying an external preparation to skin to suppress adhesion of air pollutants to the skin, wherein the external preparation contains the component (AI), and the component (BI), the component (BII) or the component (BIII), and the ratio by mass of the content of the component (BI), the component (BII) or the component (BIII) to the content of the component (AI) in the external preparation each falls within a specific range. Component (AI): a hydrophobized metal oxide having an average primary particle diameter dAI of 800 nm or less. Component (BI): an ester oil. Component (BII): a nonvolatile hydrocarbon oil. Component (BIII): a nonvolatile silicone oil.

Abstract: Provided is a method for producing a coating film formed on the skin by electrostatic spraying, the coating film having good feeling and not causing damage on the coating film even after a lapse of a long time A method for producing a coating film on the skin, comprising the steps of: A) electrostatically spraying a composition X comprising a component (a) and a component (b) directly onto the skin to form a coating film on a surface of the skin: (a) one or more volatile substances selected from the group consisting of water, an alcohol and a ketone; (b) a polymer capable of forming a coating film; and B) applying a composition Y other than the composition X, comprising a component (c) and a component (d) to the skin in the order presented or in reverse order: (c) 0.5% by mass or more and less than 5% by mass of an adhesive polymer; (d) one or more selected from the group consisting of a polyol and a liquid oil.

Abstract: The present disclosure is related to 2-(2-ethoxyethoxy)ethyl-functionalized polymers; their use in foldable intraocular lenses; and methods of making the same.

Abstract: In one aspect, the present disclosure pertains to elutable coating compositions that comprise an excipient comprising a bio-degradable or bio-stable polymer selected from a poly(lactic-co-glycolic acid) (PLGA) or methyl cellulose (MCC), a binding agent; a therapeutic agent. In some embodiments, the elutable coating compositions further comprise a solvent, in which case such compositions may be, for example, applied to a substrate in the form of a layer and subsequently dried, thereby forming an elutable coating on the substrate.

Abstract: The present invention relates to the discovery of novel PLGA particles comprising a polypeptide adsorbed on the surface of the PLGA particles. In certain embodiments, the PLGA particles can be used to administer the polypeptide to a patient in need thereof. As compared to polypeptide-delivery formulations known in the art, the present invention demonstrates a higher relative polypeptide loading capacity. In certain embodiments, the polypeptide adsorbed on the surface of the PLGA nanoparticles does not denature or deform upon adsorption.

Abstract: Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.

Abstract: Film forming compositions and methods for preventing stains and increasing shine and gloss of teeth. The film forming compositions may include a polymer, such as a hydrophobic polymer, and an orally acceptable solvent. The hydrophobic polymer may include an acrylate component and a hydrophobic group coupled with one another. The hydrophobic group may include an alkyl chain, a polyethylene glycol, a polypropylene, a polyester, a polyorthoester, a phospholipid, a long chain fatty acid, a vinyl chloride, fluorethylene, a siloxane, a urethane, an octylacrylamide, a butylaminoethyl, a styrene, and combinations thereof.

Abstract: An oral care composition comprising zinc phosphate, stannous fluoride and an organic acid buffer system, as well as methods of using the same.

Abstract: Water-in-oil sunscreen emulsion compositions including an aqueous phase emulsified within an external fatty phase are provided. The external fatty phase includes at least one silicone fatty compound and at least about 10% by weight of organic UV filters with respect to the entire sunscreen composition. The compositions include an emulsifying silicone elastomer and a non-elastomeric silicone surfactant. The compositions further include swellable clay and pigment.

Abstract: A polysilane methacrylic polymer and processes of preparing the polysilane methacrylic polymer are provided.